Multiple Myeloma | Current Treatment: Physician Insights | US | 2019
The treatment of multiple myeloma has advanced considerably in recent years with Celgene’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remaining key cornerstones of treatment. Janssen’s targeting antibody, Darzalex, has gained numerous label expansions and experienced rapid uptake since its initial 2015 approval. Amgen’s Kyprolis and Takeda’s Ninlaro are both approved for relapsed/refractory (R/R) multiple myeloma, and both have generated considerable physician interest. The plethora of regimens used to treat multiple myeloma poses decision-making challenges both in the clinic and in drug development.
Questions Answered
- What uptake have Darzalex-based and Pomalyst-based regimens experienced in the treatment of R/R symptomatic multiple myeloma, according to surveyed hematologist-oncologists?
- What is the patient share of key therapies and regimens used to treat newly diagnosed and R/R multiple myeloma?
- How do drug-treatment rates vary between key multiple myeloma patient segments according to stage of disease and line of therapy?
- What drivers and obstacles influence treatment decisions in the newly diagnosed symptomatic multiple myeloma setting for select key regimens?
Product Description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of 102 hematologist-oncologists in the United States fielded in January 2019.
Key drugs covered: Revlimid, Pomalyst, Velcade, Kyprolis, Darzalex, Empliciti, Ninlaro, Farydak.
